These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 18031092)

  • 1. [Not Available].
    Holt DW; Johnston A
    BioDrugs; 1997 Mar; 7(3):175-97. PubMed ID: 18031092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclosporin. A review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral).
    Noble S; Markham A
    Drugs; 1995 Nov; 50(5):924-41. PubMed ID: 8586033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation.
    Dunn CJ; Wagstaff AJ; Perry CM; Plosker GL; Goa KL
    Drugs; 2001; 61(13):1957-2016. PubMed ID: 11708766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclosporin microemulsion (Neoral). A pharmacoeconomic review of its use compared with standard cyclosporin in renal and hepatic transplantation.
    Coukell AJ; Plosker GL
    Pharmacoeconomics; 1998 Dec; 14(6):691-708. PubMed ID: 10346420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new microemulsion formulation of cyclosporin: pharmacokinetic and clinical features.
    Friman S; Bäckman L
    Clin Pharmacokinet; 1996 Mar; 30(3):181-93. PubMed ID: 8882300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absorption of cyclosporin from conventional and new microemulsion oral formulations in liver transplant recipients with external biliary diversion.
    Trull AK; Tan KK; Tan L; Alexander GJ; Jamieson NV
    Br J Clin Pharmacol; 1995 Jun; 39(6):627-31. PubMed ID: 7654480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacokinetics of cyclosporin.
    Ptachcinski RJ; Venkataramanan R; Burckart GJ
    Clin Pharmacokinet; 1986; 11(2):107-32. PubMed ID: 3514043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How to convert from traditional cyclosporine to the microemulsion formulation in stable renal transplant patients?
    Gaspari F; Perico N; Pisoni R; Anedda MF; Signorini O; Caruso R; Gotti E; Remuzzi G
    Clin Transplant; 1998 Oct; 12(5):379-90. PubMed ID: 9787945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. International Sandimmun Neoral Study Group.
    Keown P; Niese D
    Kidney Int; 1998 Sep; 54(3):938-44. PubMed ID: 9734620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C2 monitoring strategy for optimising cyclosporin immunosuppression from the Neoral formulation.
    Levy GA
    BioDrugs; 2001; 15(5):279-90. PubMed ID: 11437692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of oral cyclosporine (Neoral) in heart transplant recipients during the immediate period after surgery.
    Banner NR; David OJ; Leaver N; Davis J; Breen J; Johnston A; Yacoub MH
    Transpl Int; 2002 Dec; 15(12):649-54. PubMed ID: 12478413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relative bioavailability of cyclosporin from conventional and microemulsion formulations in heart-lung transplant candidates with cystic fibrosis.
    Tan KK; Trull AK; Uttridge JA; Wallwork J
    Eur J Clin Pharmacol; 1995; 48(3-4):285-9. PubMed ID: 7589056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Pharmacokinetics of Once-Daily Tacrolimus in Solid-Organ Transplant Patients.
    Staatz CE; Tett SE
    Clin Pharmacokinet; 2015 Oct; 54(10):993-1025. PubMed ID: 26038096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetic model to predict steady-state exposure to once-daily cyclosporin microemulsion in renal transplant recipients.
    Schädeli F; Marti HP; Frey FJ; Uehlinger DE
    Clin Pharmacokinet; 2002; 41(1):59-69. PubMed ID: 11825097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclosporin A (Neoral) in pediatric organ transplantation. Neoral Pediatric Study Group.
    Hoyer PF
    Pediatr Transplant; 1998 Feb; 2(1):35-9. PubMed ID: 10084758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclosporin pharmacokinetics in paediatric transplant recipients.
    Cooney GF; Habucky K; Hoppu K
    Clin Pharmacokinet; 1997 Jun; 32(6):481-95. PubMed ID: 9195117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of absorption profiling on efficacy and safety of cyclosporin therapy in transplant recipients.
    Belitsky P; Dunn S; Johnston A; Levy G
    Clin Pharmacokinet; 2000 Aug; 39(2):117-25. PubMed ID: 10976658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advantages of Neoral conversion in renal transplant patients.
    Vennarecci G; Pisani F; Tisone G; Buonomo O; Famulari A; Casciani CU
    Minerva Urol Nefrol; 1998 Jun; 50(2):161-4. PubMed ID: 9707972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients.
    Kuypers DR; Claes K; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y
    Clin Pharmacokinet; 2004; 43(11):741-62. PubMed ID: 15301578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic advantages of two-hour post-dose cyclosporin a level for the therapeutic drug monitoring in stable Chinese kidney transplant recipients.
    Leung CB; Szeto CC; Ho CS; Law WK; Lam CW; Li PK
    Nephron Clin Pract; 2005; 99(3):c68-72. PubMed ID: 15650318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.